TY - JOUR AU - Cha, J. H. AU - Chan, L. C. AU - Li, C. W. AU - Hsu, J. L. AU - Hung, M. C. PY - 2019 DA - 2019// TI - Mechanisms controlling PD-L1 expression in cancer JO - Mol Cell VL - 76 UR - https://doi.org/10.1016/j.molcel.2019.09.030 DO - 10.1016/j.molcel.2019.09.030 ID - Cha2019 ER - TY - JOUR AU - Akinleye, A. AU - Rasool, Z. PY - 2019 DA - 2019// TI - Immune checkpoint inhibitors of PD-L1 as cancer therapeutics JO - J Hematol Oncol VL - 12 UR - https://doi.org/10.1186/s13045-019-0779-5 DO - 10.1186/s13045-019-0779-5 ID - Akinleye2019 ER - TY - JOUR AU - Sun, C. AU - Mezzadra, R. AU - Schumacher, T. N. PY - 2018 DA - 2018// TI - Regulation and function of the PD-L1 checkpoint JO - Immunity VL - 48 UR - https://doi.org/10.1016/j.immuni.2018.03.014 DO - 10.1016/j.immuni.2018.03.014 ID - Sun2018 ER - TY - JOUR AU - Li, X. AU - Shao, C. AU - Shi, Y. AU - Han, W. PY - 2018 DA - 2018// TI - Lessons learned from the blockade of immune checkpoints in cancer immunotherapy JO - J Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-018-0578-4 DO - 10.1186/s13045-018-0578-4 ID - Li2018 ER - TY - JOUR AU - Bardhan, K. AU - Anagnostou, T. AU - Boussiotis, V. A. PY - 2016 DA - 2016// TI - The PD1:PD-L1/2 pathway from discovery to clinical implementation JO - Front Immunol VL - 7 UR - https://doi.org/10.3389/fimmu.2016.00550 DO - 10.3389/fimmu.2016.00550 ID - Bardhan2016 ER - TY - JOUR AU - Yi, M. AU - Yu, S. AU - Qin, S. AU - Liu, Q. AU - Xu, H. AU - Zhao, W. PY - 2018 DA - 2018// TI - Gut microbiome modulates efficacy of immune checkpoint inhibitors JO - J Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-018-0592-6 DO - 10.1186/s13045-018-0592-6 ID - Yi2018 ER - TY - JOUR AU - Jiang, X. AU - Wang, J. AU - Deng, X. AU - Xiong, F. AU - Ge, J. AU - Xiang, B. PY - 2019 DA - 2019// TI - Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape JO - Mol Cancer VL - 18 UR - https://doi.org/10.1186/s12943-018-0928-4 DO - 10.1186/s12943-018-0928-4 ID - Jiang2019 ER - TY - JOUR AU - Sanmamed, M. F. AU - Chen, L. PY - 2018 DA - 2018// TI - A paradigm shift in cancer immunotherapy: from enhancement to normalization JO - Cell VL - 175 UR - https://doi.org/10.1016/j.cell.2018.09.035 DO - 10.1016/j.cell.2018.09.035 ID - Sanmamed2018 ER - TY - JOUR AU - Reck, M. AU - Rodríguez-Abreu, D. AU - Robinson, A. G. AU - Hui, R. AU - Csőszi, T. AU - Fülöp, A. PY - 2016 DA - 2016// TI - Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1606774 DO - 10.1056/NEJMoa1606774 ID - Reck2016 ER - TY - JOUR AU - Motzer, R. J. AU - Escudier, B. AU - McDermott, D. F. AU - George, S. AU - Hammers, H. J. AU - Srinivas, S. PY - 2015 DA - 2015// TI - Nivolumab versus everolimus in advanced renal-cell carcinoma JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1510665 DO - 10.1056/NEJMoa1510665 ID - Motzer2015 ER - TY - JOUR AU - Robert, C. AU - Schachter, J. AU - Long, G. V. AU - Arance, A. AU - Grob, J. J. AU - Mortier, L. PY - 2015 DA - 2015// TI - Pembrolizumab versus Ipilimumab in advanced melanoma JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1503093 DO - 10.1056/NEJMoa1503093 ID - Robert2015 ER - TY - JOUR AU - Muro, K. AU - Chung, H. C. AU - Shankaran, V. AU - Geva, R. AU - Catenacci, D. AU - Gupta, S. PY - 2016 DA - 2016// TI - Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)00175-3 DO - 10.1016/S1470-2045(16)00175-3 ID - Muro2016 ER - TY - JOUR AU - El-Khoueiry, A. B. AU - Sangro, B. AU - Yau, T. AU - Crocenzi, T. S. AU - Kudo, M. AU - Hsu, C. PY - 2017 DA - 2017// TI - Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial JO - Lancet VL - 389 UR - https://doi.org/10.1016/S0140-6736(17)31046-2 DO - 10.1016/S0140-6736(17)31046-2 ID - El-Khoueiry2017 ER - TY - JOUR AU - Overman, M. J. AU - McDermott, R. AU - Leach, J. L. AU - Lonardi, S. AU - Lenz, H. J. AU - Morse, M. A. PY - 2017 DA - 2017// TI - Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study JO - Lancet Oncol VL - 18 UR - https://doi.org/10.1016/S1470-2045(17)30422-9 DO - 10.1016/S1470-2045(17)30422-9 ID - Overman2017 ER - TY - JOUR AU - Bellmunt, J. AU - Wit, R. AU - Vaughn, D. J. AU - Fradet, Y. AU - Lee, J. L. AU - Fong, L. PY - 2017 DA - 2017// TI - Pembrolizumab as second-line therapy for advanced urothelial carcinoma JO - N Engl J Med VL - 376 UR - https://doi.org/10.1056/NEJMoa1613683 DO - 10.1056/NEJMoa1613683 ID - Bellmunt2017 ER - TY - JOUR AU - Ansell, S. M. AU - Lesokhin, A. M. AU - Borrello, I. AU - Halwani, A. AU - Scott, E. C. AU - Gutierrez, M. PY - 2015 DA - 2015// TI - PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1411087 DO - 10.1056/NEJMoa1411087 ID - Ansell2015 ER - TY - JOUR AU - Ferris, R. L. AU - Blumenschein, G. AU - Fayette, J. AU - Guigay, J. AU - Colevas, A. D. AU - Licitra, L. PY - 2016 DA - 2016// TI - Nivolumab for recurrent squamous-cell carcinoma of the head and neck JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1602252 DO - 10.1056/NEJMoa1602252 ID - Ferris2016 ER - TY - JOUR AU - Chung, H. C. AU - Ros, W. AU - Delord, J. P. AU - Perets, R. AU - Italiano, A. AU - Shapira-Frommer, R. PY - 2019 DA - 2019// TI - Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the Phase II KEYNOTE-158 study JO - J Clin Oncol VL - 37 UR - https://doi.org/10.1200/JCO.18.01265 DO - 10.1200/JCO.18.01265 ID - Chung2019 ER - TY - JOUR AU - Zhao, P. AU - Li, L. AU - Jiang, X. AU - Li, Q. PY - 2019 DA - 2019// TI - Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy JO - J Hematol Oncol VL - 12 UR - https://doi.org/10.1186/s13045-019-0738-1 DO - 10.1186/s13045-019-0738-1 ID - Zhao2019 ER - TY - JOUR AU - Yi, M. AU - Jiao, D. AU - Xu, H. AU - Liu, Q. AU - Zhao, W. AU - Han, X. PY - 2018 DA - 2018// TI - Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors JO - Mol Cancer VL - 17 UR - https://doi.org/10.1186/s12943-018-0864-3 DO - 10.1186/s12943-018-0864-3 ID - Yi2018 ER - TY - JOUR AU - Yu, H. AU - Boyle, T. A. AU - Zhou, C. AU - Rimm, D. L. AU - Hirsch, F. R. PY - 2016 DA - 2016// TI - PD-L1 expression in lung cancer JO - J Thorac Oncol VL - 11 UR - https://doi.org/10.1016/j.jtho.2016.04.014 DO - 10.1016/j.jtho.2016.04.014 ID - Yu2016 ER - TY - JOUR AU - Ribas, A. AU - Hu-Lieskovan, S. PY - 2016 DA - 2016// TI - What does PD-L1 positive or negative mean? JO - J Exp Med VL - 213 UR - https://doi.org/10.1084/jem.20161462 DO - 10.1084/jem.20161462 ID - Ribas2016 ER - TY - JOUR AU - Roemer, M. G. AU - Advani, R. H. AU - Ligon, A. H. AU - Natkunam, Y. AU - Redd, R. A. AU - Homer, H. PY - 2016 DA - 2016// TI - PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2016.66.4482 DO - 10.1200/JCO.2016.66.4482 ID - Roemer2016 ER - TY - JOUR AU - George, J. AU - Saito, M. AU - Tsuta, K. AU - Iwakawa, R. AU - Shiraishi, K. AU - Scheel, A. H. PY - 2017 DA - 2017// TI - Genomic amplification of CD274 (PD-L1) in small-cell lung cancer JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-1069 DO - 10.1158/1078-0432.CCR-16-1069 ID - George2017 ER - TY - JOUR AU - Twa, D. D. AU - Chan, F. C. AU - Ben-Neriah, S. AU - Woolcock, B. W. AU - Mottok, A. AU - Tan, K. L. PY - 2014 DA - 2014// TI - Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma JO - Blood VL - 123 UR - https://doi.org/10.1182/blood-2013-10-535443 DO - 10.1182/blood-2013-10-535443 ID - Twa2014 ER - TY - JOUR AU - Howe, F. S. AU - Fischl, H. AU - Murray, S. C. AU - Mellor, J. PY - 2017 DA - 2017// TI - Is H3K4me3 instructive for transcription activation? JO - BioEssays VL - 39 UR - https://doi.org/10.1002/bies.201600095 DO - 10.1002/bies.201600095 ID - Howe2017 ER - TY - STD TI - Lu C, Paschall AV, Shi H, Savage N, Waller JL, Sabbatini ME, et al. The MLL1-H3K4me3 axis-mediated pd-l1 expression and pancreatic cancer immune evasion. J Natl Cancer Inst. 2017;109. ID - ref27 ER - TY - JOUR AU - Zhang, T. AU - Cooper, S. AU - Brockdorff, N. PY - 2015 DA - 2015// TI - The interplay of histone modifications—writers that read JO - EMBO Rep VL - 16 UR - https://doi.org/10.15252/embr.201540945 DO - 10.15252/embr.201540945 ID - Zhang2015 ER - TY - JOUR AU - Xiao, G. AU - Jin, L. L. AU - Liu, C. Q. AU - Wang, Y. C. AU - Meng, Y. M. AU - Zhou, Z. G. PY - 2019 DA - 2019// TI - EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma JO - J Immunother Cancer VL - 7 UR - https://doi.org/10.1186/s40425-019-0784-9 DO - 10.1186/s40425-019-0784-9 ID - Xiao2019 ER - TY - JOUR AU - Emran, A. A. AU - Chatterjee, A. AU - Rodger, E. J. AU - Tiffen, J. C. AU - Gallagher, S. J. AU - Eccles, M. R. PY - 2019 DA - 2019// TI - Targeting DNA methylation and EZH2 activity to overcome melanoma resistance to immunotherapy JO - Trends Immunol VL - 40 UR - https://doi.org/10.1016/j.it.2019.02.004 DO - 10.1016/j.it.2019.02.004 ID - Emran2019 ER - TY - JOUR AU - Li, H. AU - Chiappinelli, K. B. AU - Guzzetta, A. A. AU - Easwaran, H. AU - Yen, R. W. AU - Vatapalli, R. PY - 2014 DA - 2014// TI - Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers JO - Oncotarget VL - 5 UR - https://doi.org/10.18632/oncotarget.1782 DO - 10.18632/oncotarget.1782 ID - Li2014 ER - TY - STD TI - Chatterjee A, Rodger EJ, Ahn A, Stockwell PA, Parry M, Motwani J, et al. Marked global DNA hypomethylation is associated with constitutive PD-L1 expression in melanoma. iScience. 2018;4:312–25. ID - ref32 ER - TY - JOUR AU - Micevic, G. AU - Thakral, D. AU - McGeary, M. AU - Bosenberg, M. W. PY - 2019 DA - 2019// TI - PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival JO - Pigment Cell Melanoma Res VL - 32 UR - https://doi.org/10.1111/pcmr.12745 DO - 10.1111/pcmr.12745 ID - Micevic2019 ER - TY - JOUR AU - Franzen, A. AU - Vogt, T. J. AU - Müller, T. AU - Dietrich, J. AU - Schröck, A. AU - Golletz, C. PY - 2018 DA - 2018// TI - PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas JO - Oncotarget VL - 9 UR - https://doi.org/10.18632/oncotarget.23080 DO - 10.18632/oncotarget.23080 ID - Franzen2018 ER - TY - JOUR AU - Goltz, D. AU - Gevensleben, H. AU - Dietrich, J. AU - Dietrich, D. PY - 2017 DA - 2017// TI - PD-L1 (CD274) promoter methylation predicts survival in colorectal cancer patients JO - Oncoimmunology VL - 6 UR - https://doi.org/10.1080/2162402X.2016.1257454 DO - 10.1080/2162402X.2016.1257454 ID - Goltz2017 ER - TY - JOUR AU - Asgarova, A. AU - Asgarov, K. AU - Godet, Y. AU - Peixoto, P. AU - Nadaradjane, A. AU - Boyer-Guittaut, M. PY - 2018 DA - 2018// TI - PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma JO - Oncoimmunology VL - 7 UR - https://doi.org/10.1080/2162402X.2017.1423170 DO - 10.1080/2162402X.2017.1423170 ID - Asgarova2018 ER - TY - JOUR AU - Zhu, T. AU - Hu, Z. AU - Wang, Z. AU - Ding, H. AU - Li, R. AU - Sun, J. PY - 2020 DA - 2020// TI - Epigenetically silenced PD-L1 confers drug resistance to anti-PD1 therapy in gastric cardia adenocarcinoma JO - Int Immunopharmacol VL - 82 UR - https://doi.org/10.1016/j.intimp.2020.106245 DO - 10.1016/j.intimp.2020.106245 ID - Zhu2020 ER - TY - JOUR AU - Clayton, A. L. AU - Hazzalin, C. A. AU - Mahadevan, L. C. PY - 2006 DA - 2006// TI - Enhanced histone acetylation and transcription: a dynamic perspective JO - Mol Cell VL - 23 UR - https://doi.org/10.1016/j.molcel.2006.06.017 DO - 10.1016/j.molcel.2006.06.017 ID - Clayton2006 ER - TY - JOUR AU - Wang, H. AU - Fu, C. AU - Du, J. AU - Wang, H. AU - He, R. AU - Yin, X. PY - 2020 DA - 2020// TI - Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells JO - J Exp Clin Cancer Res VL - 39 UR - https://doi.org/10.1186/s13046-020-1536-x DO - 10.1186/s13046-020-1536-x ID - Wang2020 ER - TY - JOUR AU - Woods, D. M. AU - Sodré, A. L. AU - Villagra, A. AU - Sarnaik, A. AU - Sotomayor, E. M. AU - Weber, J. PY - 2015 DA - 2015// TI - HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade JO - Cancer Immunol Res VL - 3 UR - https://doi.org/10.1158/2326-6066.CIR-15-0077-T DO - 10.1158/2326-6066.CIR-15-0077-T ID - Woods2015 ER - TY - JOUR AU - Shi, Y. AU - Fu, Y. AU - Zhang, X. AU - Zhao, G. AU - Yao, Y. AU - Guo, Y. PY - 2020 DA - 2020// TI - Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer JO - Cancer Immunol Immunother UR - https://doi.org/10.1007/s00262-020-02653-1 DO - 10.1007/s00262-020-02653-1 ID - Shi2020 ER - TY - JOUR AU - Deng, S. AU - Hu, Q. AU - Zhang, H. AU - Yang, F. AU - Peng, C. AU - Huang, C. PY - 2019 DA - 2019// TI - HDAC3 inhibition upregulates PD-L1 expression in B-cell lymphomas and augments the efficacy of anti-PD-L1 therapy JO - Mol Cancer Ther VL - 18 UR - https://doi.org/10.1158/1535-7163.MCT-18-1068 DO - 10.1158/1535-7163.MCT-18-1068 ID - Deng2019 ER - TY - JOUR AU - Zerdes, I. AU - Matikas, A. AU - Bergh, J. AU - Rassidakis, G. Z. AU - Foukakis, T. PY - 2018 DA - 2018// TI - Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations JO - Oncogene VL - 37 UR - https://doi.org/10.1038/s41388-018-0303-3 DO - 10.1038/s41388-018-0303-3 ID - Zerdes2018 ER - TY - JOUR AU - Garcia-Diaz, A. AU - Shin, D. S. AU - Moreno, B. H. AU - Saco, J. AU - Escuin-Ordinas, H. AU - Rodriguez, G. A. PY - 2017 DA - 2017// TI - Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression JO - Cell Rep VL - 19 UR - https://doi.org/10.1016/j.celrep.2017.04.031 DO - 10.1016/j.celrep.2017.04.031 ID - Garcia-Diaz2017 ER - TY - JOUR AU - Yao, S. AU - Jiang, L. AU - Moser, E. K. AU - Jewett, L. B. AU - Wright, J. AU - Du, J. PY - 2015 DA - 2015// TI - Control of pathogenic effector T-cell activities in situ by PD-L1 expression on respiratory inflammatory dendritic cells during respiratory syncytial virus infection JO - Mucosal Immunol VL - 8 UR - https://doi.org/10.1038/mi.2014.106 DO - 10.1038/mi.2014.106 ID - Yao2015 ER - TY - JOUR AU - Moon, J. W. AU - Kong, S. K. AU - Kim, B. S. AU - Kim, H. J. AU - Lim, H. AU - Noh, K. PY - 2017 DA - 2017// TI - IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma JO - Sci Rep VL - 7 UR - https://doi.org/10.1038/s41598-017-18132-0 DO - 10.1038/s41598-017-18132-0 ID - Moon2017 ER - TY - JOUR AU - Blazanin, N. AU - Cheng, T. AU - Carbajal, S. AU - DiGiovanni, J. PY - 2019 DA - 2019// TI - Activation of a protumorigenic IFNγ/STAT1/IRF-1 signaling pathway in keratinocytes following exposure to solar ultraviolet light JO - Mol Carcinog VL - 58 UR - https://doi.org/10.1002/mc.23073 DO - 10.1002/mc.23073 ID - Blazanin2019 ER - TY - JOUR AU - Yan, Y. AU - Zheng, L. AU - Du, Q. AU - Yan, B. AU - Geller, D. A. PY - 2020 DA - 2020// TI - Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells JO - Cancer Immunol Immunother VL - 69 UR - https://doi.org/10.1007/s00262-020-02586-9 DO - 10.1007/s00262-020-02586-9 ID - Yan2020 ER - TY - JOUR AU - Shin, D. S. AU - Zaretsky, J. M. AU - Escuin-Ordinas, H. AU - Garcia-Diaz, A. AU - Hu-Lieskovan, S. AU - Kalbasi, A. PY - 2017 DA - 2017// TI - Primary resistance to PD-1 blockade mediated by JAK1/2 mutations JO - Cancer Discov VL - 7 UR - https://doi.org/10.1158/2159-8290.CD-16-1223 DO - 10.1158/2159-8290.CD-16-1223 ID - Shin2017 ER - TY - JOUR AU - Xu, L. AU - Chen, X. AU - Shen, M. AU - Yang, D. R. AU - Fang, L. AU - Weng, G. PY - 2018 DA - 2018// TI - Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels JO - Mol Oncol VL - 12 UR - https://doi.org/10.1002/1878-0261.12135 DO - 10.1002/1878-0261.12135 ID - Xu2018 ER - TY - JOUR AU - Zhang, W. AU - Liu, Y. AU - Yan, Z. AU - Yang, H. AU - Sun, W. AU - Yao, Y. PY - 2020 DA - 2020// TI - IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma JO - J Immunother Cancer VL - 8 UR - https://doi.org/10.1136/jitc-2019-000285 DO - 10.1136/jitc-2019-000285 ID - Zhang2020 ER - TY - JOUR AU - Lamano, J. B. AU - Lamano, J. B. AU - Li, Y. D. AU - DiDomenico, J. D. AU - Choy, W. AU - Veliceasa, D. PY - 2019 DA - 2019// TI - Glioblastoma-derived IL6 induces immunosuppressive peripheral myeloid cell PD-L1 and promotes tumor growth JO - Clin Cancer Res VL - 25 UR - https://doi.org/10.1158/1078-0432.CCR-18-2402 DO - 10.1158/1078-0432.CCR-18-2402 ID - Lamano2019 ER - TY - JOUR AU - Shen, M. J. AU - Xu, L. J. AU - Yang, L. AU - Tsai, Y. AU - Keng, P. C. AU - Chen, Y. PY - 2017 DA - 2017// TI - Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway JO - Oncotarget VL - 8 UR - https://doi.org/10.18632/oncotarget.19193 DO - 10.18632/oncotarget.19193 ID - Shen2017 ER - TY - JOUR AU - Wang, X. AU - Yang, L. AU - Huang, F. AU - Zhang, Q. AU - Liu, S. AU - Ma, L. PY - 2017 DA - 2017// TI - Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells JO - Immunol Lett VL - 184 UR - https://doi.org/10.1016/j.imlet.2017.02.006 DO - 10.1016/j.imlet.2017.02.006 ID - Wang2017 ER - TY - JOUR AU - Quandt, D. AU - Jasinski-Bergner, S. AU - Müller, U. AU - Schulze, B. AU - Seliger, B. PY - 2014 DA - 2014// TI - Synergistic effects of IL-4 and TNFα on the induction of B7–H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation JO - J Transl Med VL - 12 UR - https://doi.org/10.1186/1479-5876-12-151 DO - 10.1186/1479-5876-12-151 ID - Quandt2014 ER - TY - JOUR AU - Jiang, C. AU - Yuan, F. AU - Wang, J. AU - Wu, L. PY - 2017 DA - 2017// TI - Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages JO - Immunobiology VL - 222 UR - https://doi.org/10.1016/j.imbio.2016.12.002 DO - 10.1016/j.imbio.2016.12.002 ID - Jiang2017 ER - TY - JOUR AU - Carbotti, G. AU - Barisione, G. AU - Airoldi, I. AU - Mezzanzanica, D. AU - Bagnoli, M. AU - Ferrero, S. PY - 2015 DA - 2015// TI - IL-27 induces the expression of IDO and PD-L1 in human cancer cells JO - Oncotarget VL - 6 UR - https://doi.org/10.18632/oncotarget.6530 DO - 10.18632/oncotarget.6530 ID - Carbotti2015 ER - TY - JOUR AU - Starke, A. AU - Wüthrich, R. P. AU - Waeckerle-Men, Y. PY - 2007 DA - 2007// TI - TGF-beta treatment modulates PD-L1 and CD40 expression in proximal renal tubular epithelial cells and enhances CD8 cytotoxic T-cell responses JO - Nephron Exp Nephrol VL - 107 UR - https://doi.org/10.1159/000106506 DO - 10.1159/000106506 ID - Starke2007 ER - TY - JOUR AU - Ou, J. N. AU - Wiedeman, A. E. AU - Stevens, A. M. PY - 2012 DA - 2012// TI - TNF-α and TGF-β counter-regulate PD-L1 expression on monocytes in systemic lupus erythematosus JO - Sci Rep VL - 2 UR - https://doi.org/10.1038/srep00295 DO - 10.1038/srep00295 ID - Ou2012 ER - TY - JOUR AU - David, J. M. AU - Dominguez, C. AU - McCampbell, K. K. AU - Gulley, J. L. AU - Schlom, J. AU - Palena, C. PY - 2017 DA - 2017// TI - A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells JO - Oncoimmunology VL - 6 UR - https://doi.org/10.1080/2162402X.2017.1349589 DO - 10.1080/2162402X.2017.1349589 ID - David2017 ER - TY - JOUR AU - Ni, X. Y. AU - Sui, H. X. AU - Liu, Y. AU - Ke, S. Z. AU - Wang, Y. N. AU - Gao, F. G. PY - 2012 DA - 2012// TI - TGF-β of lung cancer microenvironment upregulates B7H1 and GITRL expression in dendritic cells and is associated with regulatory T cell generation JO - Oncol Rep VL - 28 UR - https://doi.org/10.3892/or.2012.1822 DO - 10.3892/or.2012.1822 ID - Ni2012 ER - TY - JOUR AU - Akbay, E. A. AU - Koyama, S. AU - Carretero, J. AU - Altabef, A. AU - Tchaicha, J. H. AU - Christensen, C. L. PY - 2013 DA - 2013// TI - Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors JO - Cancer Discov VL - 3 UR - https://doi.org/10.1158/2159-8290.CD-13-0310 DO - 10.1158/2159-8290.CD-13-0310 ID - Akbay2013 ER - TY - JOUR AU - Gainor, J. F. AU - Shaw, A. T. AU - Sequist, L. V. AU - Fu, X. AU - Azzoli, C. G. AU - Piotrowska, Z. PY - 2016 DA - 2016// TI - EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-3101 DO - 10.1158/1078-0432.CCR-15-3101 ID - Gainor2016 ER - TY - JOUR AU - Garassino, M. C. AU - Gelibter, A. J. AU - Grossi, F. AU - Chiari, R. AU - Soto Parra, H. AU - Cascinu, S. PY - 2018 DA - 2018// TI - Italian nivolumab expanded access program in nonsquamous non-small cell lung cancer patients: results in never-smokers and EGFR-mutant patients JO - J Thorac Oncol VL - 13 UR - https://doi.org/10.1016/j.jtho.2018.04.025 DO - 10.1016/j.jtho.2018.04.025 ID - Garassino2018 ER - TY - JOUR AU - Garassino, M. C. AU - Cho, B. C. AU - Kim, J. H. AU - Mazières, J. AU - Vansteenkiste, J. AU - Lena, H. PY - 2018 DA - 2018// TI - Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study JO - Lancet Oncol VL - 19 UR - https://doi.org/10.1016/S1470-2045(18)30144-X DO - 10.1016/S1470-2045(18)30144-X ID - Garassino2018 ER - TY - JOUR AU - Yuan, J. AU - Dong, X. AU - Yap, J. AU - Hu, J. PY - 2020 DA - 2020// TI - The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy JO - J Hematol Oncol VL - 13 UR - https://doi.org/10.1186/s13045-020-00949-4 DO - 10.1186/s13045-020-00949-4 ID - Yuan2020 ER - TY - STD TI - Stutvoet TS, Kol A, de Vries EG, de Bruyn M, Fehrmann RS, Terwisscha van Scheltinga AG, et al. MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells. J Pathol. 2019;249:52–64. ID - ref67 ER - TY - JOUR AU - Jiang, X. AU - Zhou, J. AU - Giobbie-Hurder, A. AU - Wargo, J. AU - Hodi, F. S. PY - 2013 DA - 2013// TI - The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-12-2731 DO - 10.1158/1078-0432.CCR-12-2731 ID - Jiang2013 ER - TY - JOUR AU - Zhang, Y. AU - Velez-Delgado, A. AU - Mathew, E. AU - Li, D. AU - Mendez, F. M. AU - Flannagan, K. PY - 2017 DA - 2017// TI - Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer JO - Gut VL - 66 UR - https://doi.org/10.1136/gutjnl-2016-312078 DO - 10.1136/gutjnl-2016-312078 ID - Zhang2017 ER - TY - JOUR AU - Loi, S. AU - Dushyanthen, S. AU - Beavis, P. A. AU - Salgado, R. AU - Denkert, C. AU - Savas, P. PY - 2016 DA - 2016// TI - RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-1125 DO - 10.1158/1078-0432.CCR-15-1125 ID - Loi2016 ER - TY - JOUR AU - Mimura, K. AU - Kua, L. F. AU - Shiraishi, K. AU - Kee Siang, L. AU - Shabbir, A. AU - Komachi, M. PY - 2014 DA - 2014// TI - Inhibition of mitogen-activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD-L1-upregulation in contrast to interferon-γ treatment JO - Cancer Sci VL - 105 UR - https://doi.org/10.1111/cas.12503 DO - 10.1111/cas.12503 ID - Mimura2014 ER - TY - JOUR AU - Atefi, M. AU - Avramis, E. AU - Lassen, A. AU - Wong, D. J. AU - Robert, L. AU - Foulad, D. PY - 2014 DA - 2014// TI - Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-13-2797 DO - 10.1158/1078-0432.CCR-13-2797 ID - Atefi2014 ER - TY - JOUR AU - Haddadi, N. AU - Lin, Y. AU - Travis, G. AU - Simpson, A. M. AU - Nassif, N. T. AU - McGowan, E. M. PY - 2018 DA - 2018// TI - PTEN/PTENP1: 'regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy JO - Mol Cancer VL - 17 UR - https://doi.org/10.1186/s12943-018-0803-3 DO - 10.1186/s12943-018-0803-3 ID - Haddadi2018 ER - TY - JOUR AU - Mittendorf, E. A. AU - Philips, A. V. AU - Meric-Bernstam, F. AU - Qiao, N. AU - Wu, Y. AU - Harrington, S. PY - 2014 DA - 2014// TI - PD-L1 expression in triple-negative breast cancer JO - Cancer Immunol Res VL - 2 UR - https://doi.org/10.1158/2326-6066.CIR-13-0127 DO - 10.1158/2326-6066.CIR-13-0127 ID - Mittendorf2014 ER - TY - JOUR AU - Kim, Y. B. AU - Ahn, J. M. AU - Bae, W. J. AU - Sung, C. O. AU - Lee, D. PY - 2019 DA - 2019// TI - Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer JO - Int J Cancer VL - 145 UR - https://doi.org/10.1002/ijc.32140 DO - 10.1002/ijc.32140 ID - Kim2019 ER - TY - JOUR AU - Suh, K. J. AU - Sung, J. H. AU - Kim, J. W. AU - Han, S. H. AU - Lee, H. S. AU - Min, A. PY - 2017 DA - 2017// TI - EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release JO - Oncotarget VL - 8 UR - https://doi.org/10.18632/oncotarget.19194 DO - 10.18632/oncotarget.19194 ID - Suh2017 ER - TY - JOUR AU - Huang, T. Y. AU - Chang, T. C. AU - Chin, Y. T. AU - Pan, Y. S. AU - Chang, W. J. AU - Liu, F. C. PY - 2020 DA - 2020// TI - NDAT targets PI3K-mediated PD-L1 upregulation to reduce proliferation in gefitinib-resistant colorectal cancer JO - Cells VL - 9 UR - https://doi.org/10.3390/cells9081830 DO - 10.3390/cells9081830 ID - Huang2020 ER - TY - JOUR AU - Fiedler, M. AU - Schulz, D. AU - Piendl, G. AU - Brockhoff, G. AU - Eichberger, J. AU - Menevse, A. N. PY - 2020 DA - 2020// TI - Buparlisib modulates PD-L1 expression in head and neck squamous cell carcinoma cell lines JO - Exp Cell Res VL - 396 UR - https://doi.org/10.1016/j.yexcr.2020.112259 DO - 10.1016/j.yexcr.2020.112259 ID - Fiedler2020 ER - TY - JOUR AU - Lastwika, K. J. AU - Wilson, W. AU - Li, Q. K. AU - Norris, J. AU - Xu, H. AU - Ghazarian, S. R. PY - 2016 DA - 2016// TI - Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer JO - Cancer Res VL - 76 UR - https://doi.org/10.1158/0008-5472.CAN-14-3362 DO - 10.1158/0008-5472.CAN-14-3362 ID - Lastwika2016 ER - TY - JOUR AU - Song, T. L. AU - Nairismägi, M. L. AU - Laurensia, Y. AU - Lim, J. Q. AU - Tan, J. AU - Li, Z. M. PY - 2018 DA - 2018// TI - Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma JO - Blood VL - 132 UR - https://doi.org/10.1182/blood-2018-01-829424 DO - 10.1182/blood-2018-01-829424 ID - Song2018 ER - TY - JOUR AU - Ikeda, S. AU - Okamoto, T. AU - Okano, S. AU - Umemoto, Y. AU - Tagawa, T. AU - Morodomi, Y. PY - 2016 DA - 2016// TI - PD-L1 is upregulated by simultaneous amplification of the PD-L1 and JAK2 genes in non-small cell lung cancer JO - J Thorac Oncol VL - 11 UR - https://doi.org/10.1016/j.jtho.2015.09.010 DO - 10.1016/j.jtho.2015.09.010 ID - Ikeda2016 ER - TY - JOUR AU - Shen, M. AU - Xu, Z. AU - Xu, W. AU - Jiang, K. AU - Zhang, F. AU - Ding, Q. PY - 2019 DA - 2019// TI - Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway JO - J Exp Clin Cancer Res VL - 38 UR - https://doi.org/10.1186/s13046-019-1161-8 DO - 10.1186/s13046-019-1161-8 ID - Shen2019 ER - TY - JOUR AU - Chen, M. AU - Pockaj, B. AU - Andreozzi, M. AU - Barrett, M. T. AU - Krishna, S. AU - Eaton, S. PY - 2018 DA - 2018// TI - JAK2 and PD-L1 amplification enhance the dynamic expression of PD-L1 in triple-negative breast cancer JO - Clin Breast Cancer VL - 18 UR - https://doi.org/10.1016/j.clbc.2018.05.006 DO - 10.1016/j.clbc.2018.05.006 ID - Chen2018 ER - TY - JOUR AU - Bi, X. W. AU - Wang, H. AU - Zhang, W. W. AU - Wang, J. H. AU - Liu, W. J. AU - Xia, Z. J. PY - 2016 DA - 2016// TI - PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma JO - J Hematol Oncol VL - 9 UR - https://doi.org/10.1186/s13045-016-0341-7 DO - 10.1186/s13045-016-0341-7 ID - Bi2016 ER - TY - JOUR AU - Wang, W. AU - Chapman, N. M. AU - Zhang, B. AU - Li, M. AU - Fan, M. AU - Laribee, R. N. PY - 2019 DA - 2019// TI - Upregulation of PD-L1 via HMGB1-activated IRF3 and NF-κB contributes to UV radiation-induced immune suppression JO - Cancer Res VL - 79 UR - https://doi.org/10.1158/0008-5472.CAN-18-3134 DO - 10.1158/0008-5472.CAN-18-3134 ID - Wang2019 ER - TY - JOUR AU - Jin, X. AU - Ding, D. AU - Yan, Y. AU - Li, H. AU - Wang, B. AU - Ma, L. PY - 2019 DA - 2019// TI - Phosphorylated RB promotes cancer immunity by inhibiting NF-κB activation and PD-L1 expression JO - Mol Cell VL - 73 ID - Jin2019 ER - TY - JOUR AU - Xu, D. AU - Li, J. AU - Li, R. Y. AU - Lan, T. AU - Xiao, C. AU - Gong, P. PY - 2019 DA - 2019// TI - PD-L1 expression is regulated by NF-κB during EMT signaling in gastric carcinoma JO - Onco Targets Ther VL - 12 UR - https://doi.org/10.2147/OTT.S224053 DO - 10.2147/OTT.S224053 ID - Xu2019 ER - TY - JOUR AU - Li, H. AU - Xia, J. Q. AU - Zhu, F. S. AU - Xi, Z. H. AU - Pan, C. Y. AU - Gu, L. M. PY - 2018 DA - 2018// TI - LPS promotes the expression of PD-L1 in gastric cancer cells through NF-κB activation JO - J Cell Biochem VL - 119 UR - https://doi.org/10.1002/jcb.27329 DO - 10.1002/jcb.27329 ID - Li2018 ER - TY - JOUR AU - Bouillez, A. AU - Rajabi, H. AU - Jin, C. AU - Samur, M. AU - Tagde, A. AU - Alam, M. PY - 2017 DA - 2017// TI - MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer JO - Oncogene VL - 36 UR - https://doi.org/10.1038/onc.2017.47 DO - 10.1038/onc.2017.47 ID - Bouillez2017 ER - TY - JOUR AU - Roux, C. AU - Jafari, S. M. AU - Shinde, R. AU - Duncan, G. AU - Cescon, D. W. AU - Silvester, J. PY - 2019 DA - 2019// TI - Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1 JO - Proc Natl Acad Sci U S A VL - 116 UR - https://doi.org/10.1073/pnas.1819473116 DO - 10.1073/pnas.1819473116 ID - Roux2019 ER - TY - JOUR AU - Teicher, B. A. PY - 1994 DA - 1994// TI - Hypoxia and drug resistance JO - Cancer Metastasis Rev VL - 13 UR - https://doi.org/10.1007/BF00689633 DO - 10.1007/BF00689633 ID - Teicher1994 ER - TY - JOUR AU - Barsoum, I. B. AU - Smallwood, C. A. AU - Siemens, D. R. AU - Graham, C. H. PY - 2014 DA - 2014// TI - A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells JO - Cancer Res VL - 74 UR - https://doi.org/10.1158/0008-5472.CAN-13-0992 DO - 10.1158/0008-5472.CAN-13-0992 ID - Barsoum2014 ER - TY - JOUR AU - Sellam, L. S. AU - Zappasodi, R. AU - Chettibi, F. AU - Djennaoui, D. AU - Yahi-Ait Mesbah, N. AU - Amir-Tidadini, Z. C. PY - 2020 DA - 2020// TI - Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism JO - Arch Biochem Biophys VL - 690 UR - https://doi.org/10.1016/j.abb.2020.108479 DO - 10.1016/j.abb.2020.108479 ID - Sellam2020 ER - TY - JOUR AU - Meng, L. AU - Cheng, Y. AU - Tong, X. AU - Gan, S. AU - Ding, Y. AU - Zhang, Y. PY - 2018 DA - 2018// TI - Tumor oxygenation and hypoxia inducible factor-1 functional inhibition via a reactive oxygen species responsive nanoplatform for enhancing radiation therapy and abscopal effects JO - ACS Nano VL - 12 UR - https://doi.org/10.1021/acsnano.8b03590 DO - 10.1021/acsnano.8b03590 ID - Meng2018 ER - TY - JOUR AU - Dang, C. V. PY - 2012 DA - 2012// TI - MYC on the path to cancer JO - Cell VL - 149 UR - https://doi.org/10.1016/j.cell.2012.03.003 DO - 10.1016/j.cell.2012.03.003 ID - Dang2012 ER - TY - JOUR AU - Casey, S. C. AU - Tong, L. AU - Li, Y. AU - Do, R. AU - Walz, S. AU - Fitzgerald, K. N. PY - 2016 DA - 2016// TI - MYC regulates the antitumor immune response through CD47 and PD-L1 JO - Science VL - 352 UR - https://doi.org/10.1126/science.aac9935 DO - 10.1126/science.aac9935 ID - Casey2016 ER - TY - JOUR AU - Liang, M. Q. AU - Yu, F. Q. AU - Chen, C. PY - 2020 DA - 2020// TI - C-Myc regulates PD-L1 expression in esophageal squamous cell carcinoma JO - Am J Transl Res VL - 12 ID - Liang2020 ER - TY - JOUR AU - Kim, E. Y. AU - Kim, A. AU - Kim, S. K. AU - Chang, Y. S. PY - 2017 DA - 2017// TI - MYC expression correlates with PD-L1 expression in non-small cell lung cancer JO - Lung Cancer VL - 110 UR - https://doi.org/10.1016/j.lungcan.2017.06.006 DO - 10.1016/j.lungcan.2017.06.006 ID - Kim2017 ER - TY - JOUR AU - Pan, Y. AU - Fei, Q. AU - Xiong, P. AU - Yang, J. AU - Zhang, Z. AU - Lin, X. PY - 2019 DA - 2019// TI - Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1 JO - Oncoimmunology VL - 8 UR - https://doi.org/10.1080/2162402X.2019.1581529 DO - 10.1080/2162402X.2019.1581529 ID - Pan2019 ER - TY - JOUR AU - Zou, J. AU - Zhuang, M. AU - Yu, X. AU - Li, N. AU - Mao, R. AU - Wang, Z. PY - 2018 DA - 2018// TI - MYC inhibition increases PD-L1 expression induced by IFN-γ in hepatocellular carcinoma cells JO - Mol Immunol VL - 101 UR - https://doi.org/10.1016/j.molimm.2018.07.006 DO - 10.1016/j.molimm.2018.07.006 ID - Zou2018 ER - TY - JOUR AU - Han, H. AU - Jain, A. D. AU - Truica, M. I. AU - Izquierdo-Ferrer, J. AU - Anker, J. F. AU - Lysy, B. PY - 2019 DA - 2019// TI - Small-molecule MYC inhibitors suppress tumor growth and enhance immunotherapy JO - Cancer Cell VL - 36 ID - Han2019 ER - TY - JOUR AU - Shaw, A. T. AU - Engelman, J. A. PY - 2013 DA - 2013// TI - ALK in lung cancer: past, present, and future JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.44.5353 DO - 10.1200/JCO.2012.44.5353 ID - Shaw2013 ER - TY - JOUR AU - Ota, K. AU - Azuma, K. AU - Kawahara, A. AU - Hattori, S. AU - Iwama, E. AU - Tanizaki, J. PY - 2015 DA - 2015// TI - Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-15-0016 DO - 10.1158/1078-0432.CCR-15-0016 ID - Ota2015 ER - TY - JOUR AU - Shen, J. AU - Li, S. AU - Medeiros, L. J. AU - Lin, P. AU - Wang, S. A. AU - Tang, G. PY - 2020 DA - 2020// TI - PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma JO - Mod Pathol VL - 33 UR - https://doi.org/10.1038/s41379-019-0336-3 DO - 10.1038/s41379-019-0336-3 ID - Shen2020 ER - TY - JOUR AU - Drilon, A. AU - Cappuzzo, F. AU - Ou, S. I. AU - Camidge, D. R. PY - 2017 DA - 2017// TI - Targeting MET in lung cancer: will expectations finally be MET? JO - J Thorac Oncol VL - 12 UR - https://doi.org/10.1016/j.jtho.2016.10.014 DO - 10.1016/j.jtho.2016.10.014 ID - Drilon2017 ER - TY - JOUR AU - Comoglio, P. M. AU - Trusolino, L. AU - Boccaccio, C. PY - 2018 DA - 2018// TI - Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy JO - Nat Rev Cancer VL - 18 UR - https://doi.org/10.1038/s41568-018-0002-y DO - 10.1038/s41568-018-0002-y ID - Comoglio2018 ER - TY - JOUR AU - Albitar, M. AU - Sudarsanam, S. AU - Ma, W. AU - Jiang, S. AU - Chen, W. AU - Funari, V. PY - 2018 DA - 2018// TI - Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer JO - Oncotarget VL - 9 UR - https://doi.org/10.18632/oncotarget.24455 DO - 10.18632/oncotarget.24455 ID - Albitar2018 ER - TY - JOUR AU - Demuth, C. AU - Andersen, M. N. AU - Jakobsen, K. R. AU - Madsen, A. T. AU - Sørensen, B. S. PY - 2017 DA - 2017// TI - Increased PD-L1 expression in erlotinib-resistant NSCLC cells with MET gene amplification is reversed upon MET-TKI treatment JO - Oncotarget VL - 8 UR - https://doi.org/10.18632/oncotarget.19920 DO - 10.18632/oncotarget.19920 ID - Demuth2017 ER - TY - JOUR AU - Ahn, H. K. AU - Kim, S. AU - Kwon, D. AU - Koh, J. AU - Kim, Y. A. AU - Kim, K. PY - 2019 DA - 2019// TI - MET receptor tyrosine kinase regulates the expression of co-stimulatory and co-inhibitory molecules in tumor cells and contributes to PD-L1-mediated suppression of immune cell function JO - Int J Mol Sci VL - 20 UR - https://doi.org/10.3390/ijms20174287 DO - 10.3390/ijms20174287 ID - Ahn2019 ER - TY - JOUR AU - Peng, S. AU - Wang, R. AU - Zhang, X. AU - Ma, Y. AU - Zhong, L. AU - Li, K. PY - 2019 DA - 2019// TI - EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression JO - Mol Cancer VL - 18 UR - https://doi.org/10.1186/s12943-019-1073-4 DO - 10.1186/s12943-019-1073-4 ID - Peng2019 ER - TY - JOUR AU - Donati, B. AU - Lorenzini, E. AU - Ciarrocchi, A. PY - 2018 DA - 2018// TI - BRD4 and Cancer: going beyond transcriptional regulation JO - Mol Cancer VL - 17 UR - https://doi.org/10.1186/s12943-018-0915-9 DO - 10.1186/s12943-018-0915-9 ID - Donati2018 ER - TY - JOUR AU - Zhu, H. AU - Bengsch, F. AU - Svoronos, N. AU - Rutkowski, M. R. AU - Bitler, B. G. AU - Allegrezza, M. J. PY - 2016 DA - 2016// TI - BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression JO - Cell Rep VL - 16 UR - https://doi.org/10.1016/j.celrep.2016.08.032 DO - 10.1016/j.celrep.2016.08.032 ID - Zhu2016 ER - TY - JOUR AU - Hogg, S. J. AU - Vervoort, S. J. AU - Deswal, S. AU - Ott, C. J. AU - Li, J. AU - Cluse, L. A. PY - 2017 DA - 2017// TI - BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1 JO - Cell Rep VL - 18 UR - https://doi.org/10.1016/j.celrep.2017.02.011 DO - 10.1016/j.celrep.2017.02.011 ID - Hogg2017 ER - TY - JOUR AU - Sato, H. AU - Niimi, A. AU - Yasuhara, T. AU - Permata, T. B. M. AU - Hagiwara, Y. AU - Isono, M. PY - 2017 DA - 2017// TI - DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells JO - Nat Commun VL - 8 UR - https://doi.org/10.1038/s41467-017-01883-9 DO - 10.1038/s41467-017-01883-9 ID - Sato2017 ER - TY - JOUR AU - Yi, M. AU - Xu, L. AU - Jiao, Y. AU - Luo, S. AU - Li, A. AU - Wu, K. PY - 2020 DA - 2020// TI - The role of cancer-derived microRNAs in cancer immune escape JO - J Hematol Oncol VL - 13 UR - https://doi.org/10.1186/s13045-020-00848-8 DO - 10.1186/s13045-020-00848-8 ID - Yi2020 ER - TY - JOUR AU - Ashizawa, M. AU - Okayama, H. AU - Ishigame, T. AU - Thar Min, A. K. AU - Saito, K. AU - Ujiie, D. PY - 2019 DA - 2019// TI - miRNA-148a-3p regulates immunosuppression in DNA mismatch repair-deficient colorectal cancer by targeting PD-L1 JO - Mol Cancer Res VL - 17 UR - https://doi.org/10.1158/1541-7786.MCR-18-0831 DO - 10.1158/1541-7786.MCR-18-0831 ID - Ashizawa2019 ER - TY - JOUR AU - Gao, L. AU - Guo, Q. AU - Li, X. AU - Yang, X. AU - Ni, H. AU - Wang, T. PY - 2019 DA - 2019// TI - MiR-873/PD-L1 axis regulates the stemness of breast cancer cells JO - EBioMedicine VL - 41 UR - https://doi.org/10.1016/j.ebiom.2019.02.034 DO - 10.1016/j.ebiom.2019.02.034 ID - Gao2019 ER - TY - JOUR AU - Anastasiadou, E. AU - Stroopinsky, D. AU - Alimperti, S. AU - Jiao, A. L. AU - Pyzer, A. R. AU - Cippitelli, C. PY - 2019 DA - 2019// TI - Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas JO - Leukemia VL - 33 UR - https://doi.org/10.1038/s41375-018-0178-x DO - 10.1038/s41375-018-0178-x ID - Anastasiadou2019 ER - TY - JOUR AU - Chen, L. AU - Gibbons, D. L. AU - Goswami, S. AU - Cortez, M. A. AU - Ahn, Y. H. AU - Byers, L. A. PY - 2014 DA - 2014// TI - Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression JO - Nat Commun VL - 5 UR - https://doi.org/10.1038/ncomms6241 DO - 10.1038/ncomms6241 ID - Chen2014 ER - TY - JOUR AU - Sun, C. AU - Lan, P. AU - Han, Q. AU - Huang, M. AU - Zhang, Z. AU - Xu, G. PY - 2018 DA - 2018// TI - Oncofetal gene SALL4 reactivation by hepatitis B virus counteracts miR-200c in PD-L1-induced T cell exhaustion JO - Nat Commun VL - 9 UR - https://doi.org/10.1038/s41467-018-03584-3 DO - 10.1038/s41467-018-03584-3 ID - Sun2018 ER - TY - JOUR AU - Jia, L. AU - Xi, Q. AU - Wang, H. AU - Zhang, Z. AU - Liu, H. AU - Cheng, Y. PY - 2017 DA - 2017// TI - miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity JO - Biochem Biophys Res Commun VL - 488 UR - https://doi.org/10.1016/j.bbrc.2017.05.074 DO - 10.1016/j.bbrc.2017.05.074 ID - Jia2017 ER - TY - JOUR AU - Xu, S. AU - Tao, Z. AU - Hai, B. AU - Liang, H. AU - Shi, Y. AU - Wang, T. PY - 2016 DA - 2016// TI - miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint JO - Nat Commun VL - 7 UR - https://doi.org/10.1038/ncomms11406 DO - 10.1038/ncomms11406 ID - Xu2016 ER - TY - JOUR AU - Sun, J. R. AU - Zhang, X. AU - Zhang, Y. PY - 2019 DA - 2019// TI - MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1 JO - Cell Mol Biol Lett VL - 24 UR - https://doi.org/10.1186/s11658-019-0190-9 DO - 10.1186/s11658-019-0190-9 ID - Sun2019 ER - TY - JOUR AU - Qu, F. AU - Ye, J. AU - Pan, X. AU - Wang, J. AU - Gan, S. AU - Chu, C. PY - 2019 DA - 2019// TI - MicroRNA-497-5p down-regulation increases PD-L1 expression in clear cell renal cell carcinoma JO - J Drug Target VL - 27 UR - https://doi.org/10.1080/1061186X.2018.1479755 DO - 10.1080/1061186X.2018.1479755 ID - Qu2019 ER - TY - JOUR AU - Xie, W. B. AU - Liang, L. H. AU - Wu, K. G. AU - Wang, L. X. AU - He, X. AU - Song, C. PY - 2018 DA - 2018// TI - MiR-140 expression regulates cell proliferation and targets PD-L1 in NSCLC JO - Cell Physiol Biochem VL - 46 UR - https://doi.org/10.1159/000488634 DO - 10.1159/000488634 ID - Xie2018 ER - TY - JOUR AU - Wang, X. AU - Li, J. AU - Dong, K. AU - Lin, F. AU - Long, M. AU - Ouyang, Y. PY - 2015 DA - 2015// TI - Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia JO - Cell Signal VL - 27 UR - https://doi.org/10.1016/j.cellsig.2014.12.003 DO - 10.1016/j.cellsig.2014.12.003 ID - Wang2015 ER - TY - JOUR AU - Liu, J. AU - Fan, L. AU - Yu, H. AU - Zhang, J. AU - He, Y. AU - Feng, D. PY - 2019 DA - 2019// TI - Endoplasmic reticulum stress causes liver cancer cells to release exosomal miR-23a-3p and up-regulate programmed death ligand 1 expression in macrophages JO - Hepatology VL - 70 ID - Liu2019 ER - TY - JOUR AU - Liu, Z. AU - Wen, J. AU - Wu, C. AU - Hu, C. AU - Wang, J. AU - Bao, Q. PY - 2020 DA - 2020// TI - MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma JO - Aging (Albany NY) VL - 12 UR - https://doi.org/10.18632/aging.102679 DO - 10.18632/aging.102679 ID - Liu2020 ER - TY - JOUR AU - Yao, X. AU - Tu, Y. AU - Xu, Y. AU - Guo, Y. AU - Yao, F. AU - Zhang, X. PY - 2020 DA - 2020// TI - Endoplasmic reticulum stress-induced exosomal miR-27a-3p promotes immune escape in breast cancer via regulating PD-L1 expression in macrophages JO - J Cell Mol Med VL - 24 UR - https://doi.org/10.1111/jcmm.15367 DO - 10.1111/jcmm.15367 ID - Yao2020 ER - TY - JOUR AU - Sheng, Q. AU - Zhang, Y. AU - Wang, Z. AU - Ding, J. AU - Song, Y. AU - Zhao, W. PY - 2020 DA - 2020// TI - Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells JO - Clin Exp Immunol VL - 200 UR - https://doi.org/10.1111/cei.13406 DO - 10.1111/cei.13406 ID - Sheng2020 ER - TY - JOUR AU - Dong, P. AU - Xiong, Y. AU - Yu, J. AU - Chen, L. AU - Tao, T. AU - Yi, S. PY - 2018 DA - 2018// TI - Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer JO - Oncogene VL - 37 UR - https://doi.org/10.1038/s41388-018-0347-4 DO - 10.1038/s41388-018-0347-4 ID - Dong2018 ER - TY - JOUR AU - Tang, D. AU - Zhao, D. AU - Wu, Y. AU - Yao, R. AU - Zhou, L. AU - Lu, L. PY - 2018 DA - 2018// TI - The miR-3127-5p/p-STAT3 axis up-regulates PD-L1 inducing chemoresistance in non-small-cell lung cancer JO - J Cell Mol Med VL - 22 UR - https://doi.org/10.1111/jcmm.13657 DO - 10.1111/jcmm.13657 ID - Tang2018 ER - TY - JOUR AU - Yoon, C. J. AU - Chang, M. S. AU - Kim, D. H. AU - Kim, W. AU - Koo, B. K. AU - Yun, S. C. PY - 2020 DA - 2020// TI - Epstein-Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIAS3/pSTAT3 modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas JO - Gastric Cancer VL - 23 UR - https://doi.org/10.1007/s10120-020-01059-3 DO - 10.1007/s10120-020-01059-3 ID - Yoon2020 ER - TY - JOUR AU - Kataoka, K. AU - Shiraishi, Y. AU - Takeda, Y. AU - Sakata, S. AU - Matsumoto, M. AU - Nagano, S. PY - 2016 DA - 2016// TI - Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers JO - Nature VL - 534 UR - https://doi.org/10.1038/nature18294 DO - 10.1038/nature18294 ID - Kataoka2016 ER - TY - JOUR AU - Coelho, M. A. AU - Carné, T. S. AU - Rana, S. AU - Zecchin, D. AU - Moore, C. AU - Molina-Arcas, M. PY - 2017 DA - 2017// TI - Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA JO - Immunity VL - 47 ID - Coelho2017 ER - TY - JOUR AU - Yang, K. AU - Zhou, J. AU - Chen, Y. AU - Chen, Y. AU - Chen, L. AU - Zhang, P. PY - 2020 DA - 2020// TI - Angiotensin II contributes to intratumoral immunosuppressionvia induction of PD-L1 expression in non-small cell lung carcinoma JO - Int Immunopharmacol VL - 84 UR - https://doi.org/10.1016/j.intimp.2020.106507 DO - 10.1016/j.intimp.2020.106507 ID - Yang2020 ER - TY - JOUR AU - Wu, Z. AU - Huang, R. AU - Yuan, L. PY - 2019 DA - 2019// TI - Crosstalk of intracellular post-translational modifications in cancer JO - Arch Biochem Biophys VL - 676 UR - https://doi.org/10.1016/j.abb.2019.108138 DO - 10.1016/j.abb.2019.108138 ID - Wu2019 ER - TY - JOUR AU - Burr, M. L. AU - Sparbier, C. E. AU - Chan, Y. C. AU - Williamson, J. C. AU - Woods, K. AU - Beavis, P. A. PY - 2017 DA - 2017// TI - CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity JO - Nature VL - 549 UR - https://doi.org/10.1038/nature23643 DO - 10.1038/nature23643 ID - Burr2017 ER - TY - JOUR AU - Shaid, S. AU - Brandts, C. H. AU - Serve, H. AU - Dikic, I. PY - 2013 DA - 2013// TI - Ubiquitination and selective autophagy JO - Cell Death Differ VL - 20 UR - https://doi.org/10.1038/cdd.2012.72 DO - 10.1038/cdd.2012.72 ID - Shaid2013 ER - TY - JOUR AU - Mezzadra, R. AU - Sun, C. AU - Jae, L. T. AU - Gomez-Eerland, R. AU - Vries, E. AU - Wu, W. PY - 2017 DA - 2017// TI - Identification of CMTM6 and CMTM4 as PD-L1 protein regulators JO - Nature VL - 549 UR - https://doi.org/10.1038/nature23669 DO - 10.1038/nature23669 ID - Mezzadra2017 ER - TY - JOUR AU - Zhang, J. AU - Bu, X. AU - Wang, H. AU - Zhu, Y. AU - Geng, Y. AU - Nihira, N. T. PY - 2018 DA - 2018// TI - Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance JO - Nature VL - 553 UR - https://doi.org/10.1038/nature25015 DO - 10.1038/nature25015 ID - Zhang2018 ER - TY - JOUR AU - Lim, S. O. AU - Li, C. W. AU - Xia, W. AU - Cha, J. H. AU - Chan, L. C. AU - Wu, Y. PY - 2016 DA - 2016// TI - Deubiquitination and stabilization of PD-L1 by CSN5 JO - Cancer Cell VL - 30 UR - https://doi.org/10.1016/j.ccell.2016.10.010 DO - 10.1016/j.ccell.2016.10.010 ID - Lim2016 ER - TY - JOUR AU - Chan, L. C. AU - Li, C. W. AU - Xia, W. AU - Hsu, J. M. AU - Lee, H. H. AU - Cha, J. H. PY - 2019 DA - 2019// TI - IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion JO - J Clin Invest VL - 129 UR - https://doi.org/10.1172/JCI126022 DO - 10.1172/JCI126022 ID - Chan2019 ER - TY - JOUR AU - Cha, J. H. AU - Yang, W. H. AU - Xia, W. AU - Wei, Y. AU - Chan, L. C. AU - Lim, S. O. PY - 2018 DA - 2018// TI - Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1 JO - Mol Cell VL - 71 ID - Cha2018 ER - TY - JOUR AU - Li, C. W. AU - Lim, S. O. AU - Xia, W. AU - Lee, H. H. AU - Chan, L. C. AU - Kuo, C. W. PY - 2016 DA - 2016// TI - Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity JO - Nat Commun VL - 7 UR - https://doi.org/10.1038/ncomms12632 DO - 10.1038/ncomms12632 ID - Li2016 ER - TY - JOUR AU - Li, H. AU - Li, C. W. AU - Li, X. AU - Ding, Q. AU - Guo, L. AU - Liu, S. PY - 2019 DA - 2019// TI - MET inhibitors promote liver tumor evasion of the immune response by stabilizing PDL1 JO - Gastroenterology VL - 156 ID - Li2019 ER - TY - JOUR AU - Veillon, L. AU - Fakih, C. AU - Abou-El-Hassan, H. AU - Kobeissy, F. AU - Mechref, Y. PY - 2018 DA - 2018// TI - Glycosylation changes in brain cancer JO - ACS Chem Neurosci VL - 9 UR - https://doi.org/10.1021/acschemneuro.7b00271 DO - 10.1021/acschemneuro.7b00271 ID - Veillon2018 ER - TY - JOUR AU - Shi, X. AU - Zhang, D. AU - Li, F. AU - Zhang, Z. AU - Wang, S. AU - Xuan, Y. PY - 2019 DA - 2019// TI - Targeting glycosylation of PD-1 to enhance CAR-T cell cytotoxicity JO - J Hematol Oncol VL - 12 UR - https://doi.org/10.1186/s13045-019-0831-5 DO - 10.1186/s13045-019-0831-5 ID - Shi2019 ER - TY - JOUR AU - Hsu, J. M. AU - Xia, W. AU - Hsu, Y. H. AU - Chan, L. C. AU - Yu, W. H. AU - Cha, J. H. PY - 2018 DA - 2018// TI - STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion JO - Nat Commun VL - 9 UR - https://doi.org/10.1038/s41467-018-04313-6 DO - 10.1038/s41467-018-04313-6 ID - Hsu2018 ER - TY - STD TI - D'Arrigo P, Russo M, Rea A, Tufano M, Guadagno E, Del Basso De Caro ML, et al. A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma. Oncotarget. 2017;8:68291–304. ID - ref150 ER - TY - JOUR AU - Yang, Y. AU - Hsu, J. M. AU - Sun, L. AU - Chan, L. C. AU - Li, C. W. AU - Hsu, J. L. PY - 2019 DA - 2019// TI - Palmitoylation stabilizes PD-L1 to promote breast tumor growth JO - Cell Res VL - 29 UR - https://doi.org/10.1038/s41422-018-0124-5 DO - 10.1038/s41422-018-0124-5 ID - Yang2019 ER - TY - JOUR AU - Yao, H. AU - Lan, J. AU - Li, C. AU - Shi, H. AU - Brosseau, J. P. AU - Wang, H. PY - 2019 DA - 2019// TI - Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours JO - Nat Biomed Eng VL - 3 UR - https://doi.org/10.1038/s41551-019-0375-6 DO - 10.1038/s41551-019-0375-6 ID - Yao2019 ER - TY - JOUR AU - Lisberg, A. AU - Cummings, A. AU - Goldman, J. W. AU - Bornazyan, K. AU - Reese, N. AU - Wang, T. PY - 2018 DA - 2018// TI - A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naïve patients with advanced NSCLC JO - J Thorac Oncol VL - 13 UR - https://doi.org/10.1016/j.jtho.2018.03.035 DO - 10.1016/j.jtho.2018.03.035 ID - Lisberg2018 ER -